Flamel Technologies Announces Projected Release Date of First Quarter 2013 Results and Conference Call

Flamel Technologies Announces Projected Release Date of First Quarter 2013 
Results and Conference Call 
LYON, FRANCE -- (Marketwired) -- 04/23/13 --  Flamel Technologies
(NASDAQ: FLML) expects to release certain financial results for the
first quarter of 2013 on Tuesday, May 7, 2013, before the market
open. A conference call to discuss these results has been scheduled
for Tuesday, May 7th at 8:30 AM (Eastern Daylight Time). A question
and answer period will follow management's prepared remarks. 
To participate in the conference call, investors are invited to dial
888-428-9473 (U.S. and Canada) or +1-719-325-2315 (international).
The conference ID number is 8200950. The conference call webcast may
be accessed at www.flamel.com. 
A replay of the call will be available for 14 days, within a few
hours after the call ends. Investors may listen to the replay of the
call by dialing 888-203-1112 (U.S. and Canada) or +1-719-457-0820
(international), with the passcode 8200950. A replay of the webcast
will also be archived on Flamel's website for 90 days following the
About Flamel Technologies. Flamel Technologies SA's (NASDAQ: FLML)
business model is to blend high-value internally developed products
with its leading drug delivery capabilities. The Company has a
proprietary pipeline of niche specialty pharmaceutical products,
while its drug delivery platforms are focused on the goal of
developing safer, more efficacious formulations of drugs to address
unmet medical needs. Its partnered pipeline includes biological and
chemical drugs formulated with its Medusa(R) and Micropump(R) (and
its applications to the development of liquid formulations, i.e.
LiquiTime(TM) and of abuse-deterrent formulations Trigger Lock(TM))
proprietary drug delivery platforms. Several Medusa-based products
have been successfully tested in clinical trials. The Company has
developed products and manufactures Micropump-based microparticles
under FDA-audited GMP guidelines. Flamel Technologies has
collaborations with a number of leading pharmaceutical and
biotechnology companies, including GlaxoSmithKline (Coreg CR(R),
carvedilol phosphate). The Company is headquartered in Lyon, France
and has operations in St. Louis, Missouri, USA, and manufacturing
facilities in Pessac, France. Additional information may be found at
This release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995, including
certain plans, expectations, goals and projections regarding
financial results, product developments and technology platforms. All
statements that are not clearly historical in nature are
forward-looking, and the words "anticipate," "assume," "believe,"
"expect," "estimate," "plan," "will," "may," and similar expressions
are generally intended to identify forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control that could cause
actual results to differ materially from those contemplated in such
forward-looking statements. These risks include risks that the
acquisition of Eclat Pharmaceuticals may not be successfully
integrated or that certain payment acceleration events may be
triggered; the new hospital-based product under FDA review may not be
approved or such approval may be delayed; the reacquisition of the
exclusive rights to rights to develop and commercialize IFN-β XL
worldwide and identification of an alternative strategic partner for
the program may not be successful; the identified opportunities will
not result in shorter-term, high value results; clinical trial
results may not be positive or our partners may decide not to move
forward; management transition may be disruptive or not succeed as
planned; products in the development stage may not achieve scientific
objectives or milestones or meet stringent regulatory requirements;
products in development may not achieve market acceptance;
competitive products and pricing may hinder our commercial
opportunities; we may not be successful in identifying and pursuing
opportunities to develop our own product portfolio using Flamel's
technology; and the risks associated with our reliance on outside
parties and key strategic alliances. These and other risks are
described more fully in Flamel's Annual Report on Form 20-F for the
year ended December 31, 2011 that has been filed with the Securities
and Exchange Commission (SEC). All forward-looking statements
included in this release are based on information available at the
time of the release. We undertake no obligation to update or alter
our forward-looking statements as a result of new information, future
events or otherwise. 
Michael S. Anderson 
Phone: 33 (0) 4 72 78 34 34
Fax: 33 (0) 4 72 78 34 35
E-mail: anderson@flamel.com 
Investor Relations
Bob Yedid 
ICR Inc. 
Phone: 646-277-1250
Email: bob.yedid@icrinc.com 
Press spacebar to pause and continue. Press esc to stop.